A high IFN-γ-related gene expression signature and high tumor mutational burden (TMB) were associated with a low risk of relapse in a follow-up study on neoadjuvant ipilimumab plus nivolumab trials OpACIN (NCT02437279) and OpACIN-neo (NCT02977052) [94]. Here, IFNG is linked to neoplasm.